Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q96FX8

UPID:
PERP_HUMAN

ALTERNATIVE NAMES:
Keratinocyte-associated protein 1; P53-induced protein PIGPC1; Transmembrane protein THW

ALTERNATIVE UPACC:
Q96FX8; B2RB73; E1P590; Q8IWS3; Q8N1J6; Q8NC16; Q9H1C5; Q9H230

BACKGROUND:
p53 apoptosis effector related to PMP-22, with alternative names such as Keratinocyte-associated protein 1 and P53-induced protein PIGPC1, is integral to epithelial cell adhesion and apoptosis. Its role in desmosome junctions ensures epithelial layers' structural integrity, while its participation in the TP53 apoptotic pathway underscores its importance in programmed cell death.

THERAPEUTIC SIGNIFICANCE:
The protein's association with diseases like Erythrokeratodermia variabilis et progressiva 7 and Olmsted syndrome 2 highlights its clinical significance. The exploration of p53 apoptosis effector related to PMP-22's function offers promising avenues for developing novel therapeutic interventions for these challenging skin conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.